SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: satish kamat who wrote (775)3/1/2000 8:27:00 AM
From: ccryder  Read Replies (1) of 834
 
I was referring to the stock price in my remark about being pushed out of the nest too soon. I have held this stock for about 3 years and while I welcome my new net worth, running the stock up in advance of earnings is not a lasting effect so I expect some pull back. I have been following the development of NOVASTAN and thought all along US approval was only a matter of when and not if. The next drugs in the development pipeline are a different matter with both IF and WHEN questions remaining. So it is with all biotech stocks. I have been pleased that the company has not had to dilute the equity because of the year delay in getting approval for NOVASTAN but we are not out of the woods yet. It is great that if dilution comes, it won't be as great at todays stock price.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News